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There is lack of knowledge about the safety of treatment with methadone and bu‐
prenorphine as part of opioid maintenance treatment (OMT) during pregnancy. The 
purpose	of	this	study	was	to	examine	neonatal	outcomes	concerning	the	use	of	OMT	
during	pregnancy.	We	used	nationwide	 registry	 linkages	 from	 the	Czech	Republic	
(2000‐2014)	 and	 Norway	 (2004‐2013).	 We	 compared	 prenatally	 OMT–exposed	
newborns	with	(a)	newborns	of	women	hospitalized	with	opioid	use	disorder	during	
pregnancy	in	the	Czech	sample	and	(b)	newborns	with	neonatal	abstinence	syndrome	
(NAS)	 in	Norway.	We	performed	multivariate	 linear	 and	 binary	 logistic	 regression	
exploring	 the	 associations	 between	OMT	and	neonatal	 outcomes	 (growth	param‐
eters,	gestational	age,	fetal	death,	small	for	gestational	age,	Apgar	score,	and	NAS).	
Regression coefficients (b) and odds ratios (ORs) were estimated. The cohorts con‐
sisted	of	333	Czech,	and	235	Norwegian	OMT–exposed	newborns,	and	106	and	294	
newborns	 in	 the	 comparison	 groups,	 respectively.	 In	 both	 countries,	 the	 neonatal	
growth	parameters	were	similar	in	the	OMT	and	the	comparison	groups.	In	Norway,	




growth parameters as newborns of women with opioid use disorders who were not 
in	OMT	during	pregnancy.	Overall,	our	findings	do	not	suggest	that	OMT	results	in	
worse neonatal outcomes.
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1  | INTRODUC TION AND BACKGROUND
Opioid	 use	 disorder	 is	 characterized	 by	 the	 persistent	 use	 of	 opi‐
oids despite the adverse consequences of its use. Opioid mainte‐
nance	treatment	(OMT)	can	stabilize	women	and	reduce	the	risk	of	
relapse to illicit opioid use.1	The	World	Health	Organization	(WHO)	
strongly recommends women with opioid use disorders to con‐
tinue or commence OMT with either methadone or buprenorphine 
if	they	become	pregnant,	despite	the	meager	evidence	behind	this	
recommendation.2
Previous	 research	 has	 emphasized	 benefits	 with	 OMT	 during	
pregnancy.	If	left	untreated,	opioid	use	disorders	during	pregnancy	
are	associated	with	a	range	of	obstetric	and	neonatal	complications,	
such	 as	 spontaneous	 abortions,	 intrauterine	 growth	 retardation,	
preterm	 birth,	 and	 low	 Apgar	 score.3	 Since	 methadone	 mainte‐
nance	treatment	was	introduced	in	the	US	in	the	late	1960s,	stud‐
ies	have	 reported	beneficial	 effects,	 such	as	 reduced	 incidence	of	
obstetric	and	fetal	complications,	neonatal	morbidity	and	mortality,	
from methadone therapy compared to illicit heroin use during preg‐
nancy.4‐6 Maintenance treatment with buprenorphine has later been 
shown to be comparable to that of methadone.7,8
OMT	is,	however,	also	associated	with	disadvantages.	Neonates	
exposed	to	opioid	agonist	therapy	have	higher	rates	of	adverse	neo‐
natal outcomes compared to neonates in the general population. 
There is evidence of high rates of neonatal abstinence syndrome 
(NAS),	lower	birth	weight,	length,	and	head	circumference	as	well	
as increased rates of perinatal mortality.9‐11 The incidence and se‐
verity	of	NAS	are	not	only	higher	after	opioid	agonist	therapy	when	
compared to the general population; it seems to be higher after 
exposure	to	methadone	than	after	exposure	to	heroin.6
With	an	increasing	focus	on	preventing	harm	to	the	unborn	child,	
the low evidence behind OMT has resulted in critical questions from 
pregnant	woman,	clinicians,	researchers,12,13	policymakers,	and	pol‐
iticians about the safety of OMT during pregnancy.
Previous	studies	have	several	weaknesses,	 including	one	major	
concern of unmeasured confounding. Most studies only compare 
newborns of women in OMT during pregnancy with newborns of 
women	 from	the	general	population.	Women	 in	 these	 two	groups	
have	 very	 different	 confounder	 distributions,	 and	 comparison	 be‐
tween	them	is	therefore	not	suitable.	Using	appropriate	comparison	
groups is one way to come closer to an unbiased association. Many 
of	the	studies	were	also	conducted	several	years	ago,	and	often	in	
selected populations. Many were performed in countries where the 
quality	of	health	care	differs	for	different	patient	populations,	mak‐
ing a comparison between groups difficult.7,14‐18
Moreover,	 OMT	 has	 changed	 substantially	 since	 methadone	
was first introduced and since the early studies were conducted: 
more	 pharmacological	 options	 have	 been	 introduced,	 and	 inclu‐
sion	and	exclusion	criteria	for	OMT	have	changed.	In	light	of	these	
changes,	exploring	these	questions	in	new	settings	and	using	new	
approaches may contribute to shed more light on the problem. 
Use	of	data	 from	nationwide	health	registries	 is	a	new	approach	
that makes it possible to address several of the limitations from 
earlier studies.19	 Linking	 data	 from	multiple	 registries	 allows	 for	
large,	unselected	study	populations	and	identification	of	relevant	
comparison groups.
To increase the knowledge about the safety of OMT treatment 
during	pregnancy,	we	utilize	nationwide	registry	data	from	two	dif‐
ferent	European	countries	to	study	associations	between	OMT	ex‐
posure and adverse neonatal outcomes in newborns. To reduce the 
problem	of	unmeasured	confounding,	we	compared	newborns	born	
to women who were in OMT during pregnancy to newborns whose 
mothers had indications of opioid use disorders but who were not in 
OMT during pregnancy.
2  | MATERIAL S AND METHODS
2.1 | Study design
The study is an observational cohort study with two national co‐
horts based on linkages of nationwide registries.
2.2 | Setting
OMT	became	available	for	pregnant	women	in	1997	in	the	Czech	
Republic	 and	 in	 1998	 in	 Norway.20,21	 In	 both	 countries,	 OMT	 is	
provided predominantly in an outpatient setting where metha‐
done,	 buprenorphine,	 and	 buprenorphine/naloxone	 are	 used	 as	
drugs.	 In	the	Czech	Republic,	methadone	 is	dispensed	 in	special‐
ized	 facilities	 free	 of	 charge,	 while	 buprenorphine–based	 drugs	
are available in community pharmacies and are typically fully paid 
by	the	patient.	In	Norway,	most	pregnant	women	in	OMT	receive	




with personal identification numbers. This enables linkages of data 
between	different	registries	on	an	individual	level,	and	on	family	lev‐
els	such	as	between	mother	and	child.	A	more	detailed	description	of	
the data sources is provided elsewhere.8,22,23
2.4 | Registries in the Czech Republic
In	the	Czech	Republic,	physicians	are	obliged	by	law	to	report	data	to	
the national health registries.
2.4.1 | National Registry of Reproduction Health 
(NRRH)
The	NRRH	 includes	 information	 about	 all	women	 and	 their	 children	
during	pregnancy,	delivery,	and	puerperium.	For	instance,	maternal	var‐
iables	such	as	demographic	and	socioeconomic	data,	alcohol,	tobacco,	
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and illegal drug use during pregnancy and information about the deliv‐
ery	are	included	in	the	registry.	Information	about	the	newborn,	such	as	
birth	parameters,	congenital	malformations,	and	death,	is	also	included.
2.4.2 | The National Registry of Addiction 
Treatment (NRAT)
The	NRAT	contains	data	on	all	patients	starting	and	terminating	dif‐
ferent	 addiction	 treatments.	 It	 includes,	 for	 instance,	 information	
about	patients	who	receive	OMT,	such	as	date	of	treatment	initiation	
and termination and type of OMT drug.
2.4.3 | The National Registry of 
Hospitalized Patients
The	 NRIT	 includes	 information	 on	 every	 episode	 of	 all	 types	 of	
hospitalizations,	 including	 information	 on	 dates	 of	 admission	 and	




2.5.1 | The Medical Birth Registry of Norway 
(MBRN)
The	MBRN	is	based	on	a	compulsory	notification	of	every	birth	or	
late abortion from physicians or midwives attending the birth. The 
MBRN	includes	information	concerning	all	births	and	late	abortions	
from the 12th gestational week and onwards. The registry includes 
information	 concerning	 pregnancy,	 delivery,	 and	 the	 newborn.	
Maternal	data	are	also	collected,	such	as	demographic	and	socioeco‐
nomic backgrounds of the pregnant women and also tobacco smok‐
ing	during	pregnancy.	 Information	 about	 neonatal	 outcomes,	 such	
as	gestational	age,	birth	parameters,	NAS,	and	congenital	malforma‐
tions,	are	also	included.
2.5.2 | The Norwegian Prescription Database 
(NorPD)




formation on the drug is registered. The drugs are classified according 
to	the	Anatomical	Therapeutic	Chemical	(ATC)	classification	system.24
2.5.3 | Statistics Norway (SSB)
From	 Statistics	 Norway	 we	 included	 information	 about	 maternal	
education.	Educational	institutions	are	obliged	to	report	completed	
education	on	an	individual	level	to	SSB.
2.6 | Study population and study period
The study populations were pregnant women and their children 




nancy or not in OMT.









In	 Norway,	 NorPD	 was	 used	 to	 identify	 women	 using	 OMT	
drugs. Those who were dispensed OMT drugs at least once during 




to	 approximately	 10	mg/day	 in	 pregnancy,	while	women	who	 use	
methadone on average receive a total amount of about 65 mg/day. 
Approximately	80%	of	the	OMT	drugs	are	dispensed	at	pharmacies	
both early and late in the pregnancy. This suggests that they used 
these drugs throughout their pregnancy.
2.8 | Outcomes
The outcomes studied were neonatal outcomes identified in the 
NRRH	 or	 MBRN,	 and	 included:	 gestational	 age,	 preterm	 birth	






We	obtained	 information	 on	 sociodemographic	 variables	 and	 life‐
style	from	the	NRRH	in	the	Czech	Republic	and	from	the	MBRN	and	
SSB	 in	 Norway.	 This	 information	 included	 age	 and	 marital	 status	
(registered	as	not	married,	married	or	unknown;	in	Norway,	the	mar‐
ried category also included living with a partner). Information about 
education	was	 provided	 in	 the	 following	 categories:	 primary,	 sec‐
ondary,	university,	or	unknown.	Information	about	occupation	was	
only	 available	 in	 the	 Czech	 Republic,	 and	 included	 the	 categories	
unemployed,	 employed	and	unknown.	 Information	on	 recreational	
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To be able to study the safety of the OMT in pregnancy we created 
relevant but different comparison groups in the two countries by 
identifying pregnant women with indications of opioid use disorders 
who were not in OMT during pregnancy.
For	the	Czech	comparison	group,	we	selected	pregnant	women	
who,	 according	 to	 the	NRIT,	 had	 been	 hospitalized	 during	 preg‐
nancy with a diagnosis at discharge indicating that she had an 
opioid	use	disorder	 (F11.X	“mental	or	behavioral	disorder	due	to	
opioid	use”	according	to	the	International	Statistical	Classification	













could	 not	 have	 received	OMT	during	 pregnancy,	 according	 to	 the	
NorPD.
2.11 | Analysis strategy and statistics
In a previous study using the same nationwide registry data as in this 
study,8 we did not find any significant differences in risks of adverse 
neonatal	 outcomes	 between	 prenatal	 exposure	 to	 methadone	 or	
buprenorphine.	Thus	in	this	study,	we	collapsed	the	buprenorphine	
and	methadone–treated	women	 into	 one	OMT–exposed	 group	 in	
each	country.	Then,	in	each	country,	we	compared	the	OMT	group	
with	the	comparison	group	 in	that	country.	First,	we	present	soci‐
odemographic background and substance use during pregnancy. 
Next,	we	focus	on	descriptive	statistics	(mean,	standard	deviation,	
percentages	with	95%	confidence	intervals)	on	neonatal	outcomes,	
restricted	 to	 singleton	 births	 in	 both	 countries.	 Growth	 param‐
eters	 (except	SGA)	were	 restricted	 to	 term	births	 (≥37	gestational	
weeks).	Gestational	age,	SGA,	and	Apgar	scores	were	restricted	to	
live births. Confidence Intervals for proportions were calculated 
using	the	continuity–corrected	score	interval	method.26	Linear	and	
logistic regression analyses were performed to investigate the as‐
sociation	 between	 OMT	 use	 in	 pregnancy	 (yes/no	 ‐	 independent	
variable)	 and	 different	 neonatal	 outcomes	 (growth	 parameters,	
gestational	age,	fetal	death,	small	for	gestational	age,	Apgar	score,	
and	NAS	‐	dependent	variable).	Associations	were	shown	as	regres‐
sion coefficients (b) for continuous outcomes and odds ratios (ORs) 
for	 dichotomous	 outcomes	 both	 with	 95%	 confidence	 intervals.	
Unadjusted	and	adjusted	b	and	ORs	were	estimated.	The	following	






borns compared to newborns of women in OMT before and after 
(but not during) pregnancy and compared to all the children in the 
general population.
2.12 | Ethics
The	 study	was	approved	by	 the	 Institutional	Review	Board	of	 the	
General	University	Hospital	in	Prague	(IRB00002705),	the	Regional	





while 106 had opioid use disorder without being in OMT during 
pregnancy.	In	Norway,	we	identified	235	women	who	were	in	OMT	
during	 pregnancy,	 while	 294	 had	 indications	 of	 opioid	 use	 disor‐
der but were not in OMT during pregnancy. Tables 1 and 2 display 
maternal	 background	 characteristics.	 In	 both	 countries,	women	 in	
the comparison groups were younger than women in OMT. In the 
Norwegian	 sample,	 the	 pregnant	 women	 in	 the	 OMT	 group	 had	
lower	education	levels	(primary	education	71.5%	versus	50.0%)	and	
higher	smoking	prevalence	(68.5%	versus	57.2%)	during	pregnancy	
than the comparison group (Table 2).
3.2 | Neonatal outcomes – descriptive statistics
Table 3 shows that most neonatal outcomes were similar in the OMT 
group	 and	 the	 comparison	 group	 in	 both	 countries.	 In	 the	 Czech	
Republic,	the	gestational	age	was	similar	between	the	OMT‐exposed	
and	the	comparison	group	(38.4	weeks),	while	in	Norway	the	OMT‐
exposed	had	0.9	weeks	 longer	 gestational	 age	 than	 those	not	 ex‐
posed.	 Similarly	 the	 proportion	with	 preterm	 birth	was	 about	 the	
same	in	the	OMT‐exposed	and	not	exposed	in	the	Czech	Republic	
(16.9%	and	14.4%),	while	in	Norway	the	proportion	in	the	OMT‐ex‐
posed	was	about	half	of	 that	 in	 the	not	exposed	group	 (7.0%	ver‐
sus	15.0%).	Overall,	the	differences	in	neonatal	outcomes	between	
the	 OMT‐exposed	 and	 not	 exposed	 were	 negligible	 in	 the	 Czech	
Republic.	Independent	of	exposure	to	OMT	or	not,	the	mean	growth	
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parameters	 (birth	 weight,	 length,	 and	 head	 circumference)	 were	
lower	in	the	Czech	Republic	than	in	Norway.
3.3 | Neonatal outcomes – regression analyses
Table	4	shows	the	results	of	 linear	and	logistic	regression	analyses	
on birth outcomes comparing the OMT group to the comparison 
group in each country. The regression analysis of the OMT group 
versus the comparison group showed statistically significant ef‐
fects	 in	Norway:	gestational	age	(unadjusted	b	=	0.93	weeks),	pre‐
term	birth	(unadjusted	OR	=	0.44),	and	low	Apgar	score	at	5	minutes	
(unadjusted	OR	=	0.26).	After	 adjustment	 for	 confounding	 factors	
the	 risk	 estimates	 of	 OMT	 exposure	 compared	 to	 no	 exposure	





cantly associated with a difference in any of the neonatal outcomes 
in	the	Czech	cohort.
3.4 | Supplementary tables
Tables	 S1	 and	 S2	 show	 background	 characteristics	 and	 the	 neo‐
natal outcomes of the groups of women who were in OMT during 
pregnancy or who were in OMT before and after but not during 
pregnancy,	and	all	pregnant	women	and	their	children	(the	general	
population	of	pregnant	women)	in	both	countries,	respectively.	The	
groups of women in both countries who at any time had received 
OMT differed from the pregnant women in the general population 
in	that	they	had	lower	education,	fewer	were	married	or	living	with	
a	 partner,	 and	more	 of	 them	 smoked	 (Table	 S1).	 Concerning	 neo‐
natal	outcomes	 in	the	Czech	Republic,	gestational	age	and	growth	
parameters were quite similar in newborns of women who at some 
 
Czech Republic
OMT (n = 333) No OMTa (n = 106)
n % 95% CI n % 95% CI
Age,	y
≤24 98 29.4 24.7‐34.7 74 69.8 60.0‐78.2
25‐29 139 41.7 36.4‐47.3 21 19.8 13.0‐28.9
30‐34 77 23.1 18.8‐28.1 8 7.5 3.6‐14.8
≥35 19 5.7 3.6‐8.9 3 2.8 0.7‐8.7
Marital status
Not	married 266 79.9 75.1‐84.0 87 82.1 73.2‐88.6
Married 49 14.7 11.2‐19.9 10 9.4 4.9‐17.1
Unknown 18 5.4 3.3‐8.6 9 8.5 4.2‐15.9
Education
Primary 159 47.7 42.3‐53.3 61 57.5 47.6‐67.0
Secondary 154 46.2 40.8‐51.8 42 39.6 30.4‐49.6
University 4 1.2 0.4‐3.3 0 0 0.0‐3.4
Unknown 16 4.8 2.9‐7.8 3 2.8 0.7‐8.7
Occupation
Unemployed 274 82.3 77.7‐86.1 96 90.6 82.3‐95.1
Employed 25 7.5 5.0‐11.0 10 9.4 4.9‐17.1
Unknown 34 10.2 7.3‐14.1 0 0 0.0‐3.4
Using	of	addictive	substances	during	pregnancy
Alcohol 17 5.1 3.1‐8.2 6 5.7 2.3‐12.4
Smoking 136 40.8 35.6‐46.4 43 40.6 31.3‐50.6
Illicit drugs 129 38.7 33.5‐44.2 43 40.6 31.3‐50.6
Deliveries by multiplicity
Single 324 97.3 94.8‐98.7 106 100 96.6‐100.0
Twins and more 9 2.7 1.3‐5.3 0 0 0.0‐3.4
Abbreviation:	CI,	confidence	interval
aWomen	hospitalized	with	an	ICD‐10	F11	diagnosis	as	a	primary	or	secondary	diagnosis	during	
pregnancy were included. 
TA B L E  1  Socioeconomic	
characteristics	of	Czech	women	with	
indications of opioid dependence who 
received opioid maintenance treatment 
(OMT) or not during pregnancy 
(2000‐2014)
6 of 10  |     HANDAL et AL.









ing use of OMT during pregnancy using relevant comparison groups 
in	 two	nationwide	 cohorts	 of	 pregnant	women.	We	 found	no	 sig‐
nificant	 differences	 in	 neonatal	 growth	 parameters	 (birth	 weight,	
length,	and	head	circumference)	between	OMT–exposed	newborns	
and	 newborns	 of	 drug‐using	 pregnant	women	 not	 in	OMT	 during	
pregnancy. These findings were consistent in both countries. In the 
Norwegian	sample,	gestational	age	was	nearly	one	week	longer,	and	
the	odds	of	preterm	birth	 and	 low	Apgar	 score	were	 lower	 in	 the	
OMT–exposed	group.	In	the	Czech	Republic,	these	differences	were	
not observed.
Our results on growth parameters are in contrast to previous 
research,10 which suggest better neonatal outcomes in children of 
mothers in OMT compared to children of women with opioid use 
disorders	not	in	OMT.	There	can	be	several	explanations	for	these	
differences,	 such	 as	 the	more	 recent	 study	 period	 in	 the	 present	
study,	the	European	setting,	the	use	of	different	comparison	groups,	
and the registry data design of our study.
Performing	studies	on	safety	of	prenatal	OMT	exposure	in	an‐
other	setting	than	in	the	United	States,	where	the	majority	of	early	







similar risk factor profiles as women in OMT. The comparison 
group	 in	 the	Czech	Republic	 did	 not	 differ	 from	 the	OMT	group	
 
Norway
OMT (n = 235) No OMTa (n = 294)
n % 95% CI n % 95% CI
Age,	y
≤24 18 7.7 4.7‐12.0 64 21.8 17.3‐27.0
25‐29 70 29.8 24.1‐36.1 84 28.6 23.6‐34.2
30‐34 89 37.9 31.7‐44.4 80 27.2 22.3‐32.8
≥35 58 24.7 19.4‐30.8 66 22.4 17.9‐27.7
Marital status
Not	married 91 38.7 32.5‐45.3 115 39.1 33.5‐45.0
Married/living 
with partner
142 60.4 53.8‐66.7 175 59.5 53.7‐65.1
Unknown <4   4 1.4 0.4‐3.7
Education
Primary 168 71.5 65.2‐77.1 147 50.0 44.2‐55.9
Secondary 59 25.1 19.8‐31.3 78 26.5 21.7‐32.0
University 5 2.1 0.8‐5.2 48 16.3 12.4‐21.2
Unknown <4   21 7.1 4.6‐10.9
Smoking	during	pregnancy
Yes 161 68.5 62.1‐74.3 168 57.1 51.3‐62.8
No 27 11.5 7.8‐16.4 62 21.1 16.7‐26.3
Unknown 47 20.0 15.2‐25.8 64 21.8 17.3‐27.0
Deliveries by multiplicity
Single 229 97.4 94.3‐99.0 287 97.6 94.9‐99.0
Twins and more 6 2.6 1.0‐5.7 7 2.4 1.0‐5.1
<4	denotes	less	than	four	individuals	in	the	group,	exact	numbers	are	not	shown	because	of	regula‐
tion from the Registries
CI,	confidence	interval.
aWomen	who	gave	birth	to	a	child	with	neonatal	abstinence	syndrome	
TA B L E  2  Socioeconomic	
characteristics	of	Norwegian	women	
with indications of opioid dependence 
who received opioid maintenance 
treatment (OMT) or not during pregnancy 
(2004‐2013)
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concerning	background	characteristics.	 In	Norway,	 the	women	 in	
OMT smoked more and had lower education. If background char‐
acteristics	play	an	important	role	 in	affecting	neonatal	outcomes,	
the similar characteristics of the OMT and the comparison groups 
in our study suggest that the selected comparison groups were 
suitable for studying adverse outcomes of OMT during pregnancy. 
However,	it	should	be	noted	that	the	comparison	groups	were	iden‐
tified	by	different	criteria.	 In	 the	Czech	Republic,	women	with	at	
least one diagnosis indicating drug dependence during pregnancy 
constituted	the	comparison	group,	while	women	who	gave	birth	to	
a	newborn	with	NAS	comprised	the	comparison	group	in	Norway.	
This difference combined with different treatment settings 23 can 
increase	the	generalizability	of	the	findings.	Nevertheless,	the	dif‐




There	were	 differences	 in	 gestational	 age,	 preterm	 birth,	 and	
Apgar	score	between	the	OMT–exposed	and	the	nonexposed	group	
in	Norway.	 Recent	 reviews	 report	 that	 gestational	 age	 should	 be	




OMT (n = 324) No OMTb (n = 106) OMT (n = 229) No OMTc (n = 287)
Mean SD Mean SD Mean SD Mean SD
Gestational	aged (wk) 38.4 2.6 38.4 2.6 39.1 2.1 38.2 3.0
Birth	weighte (g) 3056 469 3081 404 3304 507 3286 507
Birth	lengthe (cm) 48.3 2.4 48.3 2.4 49.0 2.5 49.0 2.2
Head circumferencee (cm) 33.8 1.7 33.5 1.5 34.6 1.5 34.7 1.4
 n % (95% CI) n % (95% CI) n % (95% CI) n % (95% CI)
Abortion	induced
Yes — — — — <4 — 0 0.0	(0.0‐1.3)
No — — — — 226 98.7	(95.9‐99.7) 287 100	(98.7‐100)
Miscarriage
Yes — — — — <4 — 0 0.0	(0.0‐1.3)
No — — — — 227 99.1	(96.5‐99.8) 287 100	(98.7‐100)
Cesarean sectiond
Elective 18 5.6	(3.5‐8.9) 4 3.8	(1.2‐10.1) 25 11.0	(7.4‐16.0) 27 9.4	(6.4‐13.5)
Acute 40 12.5	(9.2‐16.7) 11 10.6	(5.7‐18.5) 26 11.5	(7.8‐16.5) 45 15.7	(11.8‐20.5)
Stillbirth 4 1.2	(0.4‐3.2) 2 1.9	(0.3‐7.3) <4 — 0 a
Preterm	birthd 54 16.9	(13.0‐21.5) 15 14.4	(8.6‐23.0) 16 7.0	(4.2‐11.4) 43 15.0	(11.2‐19.8)
Small	for	gestational	aged 
(SGA)
43 13.4	(10.0‐17.8) 10 9.6	(5.0‐17.4) 15 6.6	(3.9‐10.9) 23 8.0	(5.3‐11.9)
Apgar	scored < 7 at 1 min
Yes 28 8.8	(6.0‐12.5) 3 2.9	(0.7‐8.8) 13 5.9	(3.3‐10.1) 33 11.5	(8.2‐15.9)
No 292 91.3	(87.5‐94.0) 101 97.1	(91.2‐99.3) 207 90.4	(85.6‐93.7) 254 88.5	(84.1‐91.8)
Apgar	scored < 7 at 5 min
Yes 7 2.2	(1.0‐4.7) 2 1.9	(0.3‐7.5) 4 1.8	(0.6‐4.9) 19 6.6	(4.1‐10.3)
No 313 97.8	(95.3‐99.0) 102 98.1	(92.5‐99.7) 217 98.2	(95.1‐99.4) 268 93.4	(89.7‐95.9)
Neonatal	abstinence	syndrome	(NAS)d
Yes — — — — 120 54.1	(47.3‐60.7) 287 a
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considered as a continuum concerning the risk and severity of ad‐
verse outcomes.27,28	 Even	 though	 the	 mean	 gestational	 age	 was	
within the range of term pregnancies in both the OMT groups and 
the	comparison	groups,	it	was	almost	one	week	longer	in	the	OMT	
group	than	in	the	comparison	group	in	Norway	–	even	after	adjust‐
ing	 for	 smoking	 and	 other	 sociodemographic	 factors.	 In	 Norway,	
OMT was also associated with reduced odds of preterm birth. These 
differences	were	not	observed	in	the	Czech	sample.	As	mentioned	
above,	a	possible	explanation	may	be	that	the	Norwegian	compar‐
ison	 group	 consisted	 of	 heavier	 drug–using	 mothers	 than	 in	 the	
Czech	Republic.	Further,	a	larger	proportion	of	the	Norwegian	com‐
parison group was reported to be smoking during pregnancy than in 
the	Czech	comparison	group,	and	 it	 is	known	that	smoking	during	




group could include women who were abstinent during the last stage 
of the pregnancy.30	In	contrast,	the	Norwegian	group	consisted	of	
women	 whose	 children	 were	 born	 with	 NAS,	 indicating	 that	 the	
women	were	using	drugs,	quite	likely	opioids,	up	until	the	end	of	the	





of	 selection	 and	 recall	 bias.	 By	 using	 registry	 data,	 all	 pregnant	
women	are	identified	and	followed‐up	unless	they	move	out	of	the	




OMT vs No OMT (ref.) OMT vs No OMT (ref.)
ba 95% CI ba 95% CI
Gestational	aged
Unadjusted 0.03 0.60 to 0.55 0.93 (0.94)f 0.47‐1.39
Adjustedc 0.02 0.66 to 0.62 0.96 0.39‐1.53
Birth	weighte
Unadjusted 24.6 133.9	to	84.7 18.6 75.6 to 112.7
Adjustedc 26.6 149.1	to	96.0 62.2 50.8	to	175.1
Birth	lengthe
Unadjusted 0.02 0.56 to 0.60 0.05 0.40	to	0.50
Adjustedc 0.04 0.61	to	0.68 0.18 0.33 to 0.70
Head circumferencee
Unadjusted 0.30 0.16	to	0.74 0.13 0.41	to	0.15
Adjustedc 0.23 0.24	to	0.70 0.06 0.41	to	0.30
 ORb 95% CI ORb 95% CI
Preterm	birthd
Unadjusted 1.21 0.65‐2.24 0.44 (0.38)f 0.24‐0.81
Adjustedc 1.25 0.63‐2.46 0.35 0.16‐0.75
Small	for	gestational	age	(SGA)d
Unadjusted 1.46 0.71‐3.02 0.83 0.42‐1.63
Adjustedc 1.43 0.64‐3.18 0.58 0.26‐1.33
Apgar	scored < 7 at 5 min
Unadjusted 1.14 0.23‐5.58 0.26 (0.21)f 0.09‐0.76
Adjustedc 0.92 0.16‐5.47 0.21 0.06‐0.78
significant findings are shown in bold
ab (regression coefficients) from linear regression 




fThe b or OR from crude regression analysis when restricted to the same study sample as in ad‐
justed analysis 
TA B L E  4  Lineara 	and	binary	
logistic regressionb 	comparing	opioid	
maintenance treatment (OMT) to no such 
treatment during pregnancy in women 
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pregnant women with opioid use disorders who more often have 
a transient lifestyle.12	Another	strength	with	this	approach	is	that	
health registries identify more women in OMT than can feasibly be 
included	in	clinical	samples.	While	the	samples	of	pregnant	women	
in	OMT	 in	 our	 study	 are	 among	 the	 largest	 to	 date,	 even	 larger	
samples are needed to study rare outcomes such as stillbirths and 
miscarriages.
The	Norwegian	Prescription	Database	only	includes	information	
on prescription drugs dispensed to outpatients. If a pregnant woman 
received all her OMT drugs during pregnancy at hospital or institu‐
tion,	this	would	not	have	been	registered	 in	the	prescription	data‐
base,	and	we	would	not	have	identified	the	woman	as	in	OMT.	We	





as	 the	 comparison	 group.	 Although	 it	 is	 not	 possible	 to	 attribute	




than pregnant women in the general population were and therefore 
more suitable as a comparison group.
Neonatal	 growth	 parameters	 in	 the	 OMT–exposed	 newborns	
were	 similar	 both	 to	 the	 outcomes	 in	 newborns	 of	 drug–depen‐
dent women not in OMT during pregnancy and to the groups of 
women	using	OMT	outside	of	pregnancy,	but	not	during	pregnancy.	
However,	when	 compared	 to	 the	 general	 population,	 all	 the	 new‐
borns	 of	 women	 who	 had	 any	 indications	 of	 drug	 abuse	 before,	
during	or	after	pregnancy,	seem	to	have	worse	neonatal	outcomes	
–	 regardless	 of	 whether	 the	 woman	 received	 OMT	 during	 preg‐
nancy	or	not.	Taken	 together,	 this	might	 suggest	 that	 it	 is	not	 the	
OMT drugs themselves that are associated with worse neonatal out‐
comes,	but	other	factors	related	to	opioid	use,	such	as	comorbidity,	
socioeconomic,	and	lifestyle	factors.
Some	 critics	 have	 questioned	 the	 rationale	 for	 public	 health	
care services offering opioid maintenance treatment (OMT) during 
pregnancy. Our findings did not suggest that OMT results in worse 
outcomes	for	the	newborns	compared	to	no	treatment.	Moreover,	
we observed some important positive neonatal outcomes from OMT 
versus	no	OMT	in	the	Norwegian	sample.	Seen	in	conjunction	with	
the beneficial effects for the pregnant woman such as improved pre‐
natal	 care	 adherence	 and	 obstetrical	 outcomes,2,32‐34 our findings 
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